company background image
ARWR

Arrowhead Pharmaceuticals NasdaqGS:ARWR Stock Report

Last Price

US$33.62

Market Cap

US$3.6b

7D

-4.7%

1Y

-38.5%

Updated

08 Feb, 2023

Data

Company Financials +

Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Mkt Cap: US$3.6b

ARWR Stock Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

ARWR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Arrowhead Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arrowhead Pharmaceuticals
Historical stock prices
Current Share PriceUS$33.62
52 Week HighUS$56.25
52 Week LowUS$26.81
Beta1.01
1 Month Change11.03%
3 Month Change-3.20%
1 Year Change-38.49%
3 Year Change-20.73%
5 Year Change514.63%
Change since IPO-35.35%

Recent News & Updates

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Recent updates

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Jun 18
Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices

Apr 14

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Feb 08
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022

Jan 26

Accumulate Arrowhead For Its RNAi Pipeline

Jan 17

Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs

Nov 03

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

Oct 09
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

The Partnership Effect: Arrowhead Forges Its Future

Aug 27

Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications

Jul 06

Arrowhead and Horizon team up in potential $700M collaboration agreement

Jun 21

Arrowhead: On Target With RNAi Innovation

Jun 14

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 14
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

News Flash: 11 Analysts Think Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earnings Are Under Threat

Feb 12
News Flash: 11 Analysts Think Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earnings Are Under Threat

Here's What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shareholder Ownership Structure Looks Like

Jan 20
Here's What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shareholder Ownership Structure Looks Like

How Arrowhead Protects Its Intellectual Property

Dec 30

Analyst Forecasts For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Are Surging Higher

Nov 28
Analyst Forecasts For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Are Surging Higher

Have Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insiders Been Selling Their Stock?

Nov 27
Have Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insiders Been Selling Their Stock?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 26
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arrowhead Pharmaceuticals EPS of -$0.84

Nov 23

Shareholder Returns

ARWRUS BiotechsUS Market
7D-4.7%-0.5%1.6%
1Y-38.5%2.9%-10.8%

Return vs Industry: ARWR underperformed the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: ARWR underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is ARWR's price volatile compared to industry and market?
ARWR volatility
ARWR Average Weekly Movement11.7%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: ARWR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ARWR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989397Chris Anzalonehttps://arrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.

Arrowhead Pharmaceuticals, Inc. Fundamentals Summary

How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap?
ARWR fundamental statistics
Market CapUS$3.64b
Earnings (TTM)-US$154.52m
Revenue (TTM)US$278.34m

13.1x

P/S Ratio

-23.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARWR income statement (TTM)
RevenueUS$278.34m
Cost of RevenueUS$0
Gross ProfitUS$278.34m
Other ExpensesUS$432.85m
Earnings-US$154.52m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin100.00%
Net Profit Margin-55.51%
Debt/Equity Ratio0%

How did ARWR perform over the long term?

See historical performance and comparison